Therapy Areas: Autoimmune
Landos Biopharma Doses First Subjects in Clinical Trial of Investigational IBD Treatment
18 July 2018 - - Blacksburg, Virginia-based clinical-stage biopharmaceutical company Landos Biopharma, Inc. has dosed the first healthy subjects in a phase 1 clinical study of BT-11, a first-in-class, orally-administered, molecule targeting the LANCL2 pathway, the company said.
The phase 1 study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study intended to enroll up to 70 healthy volunteers to evaluate the safety and tolerability of BT-11. BT-11 is in development for treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
BT-11 is a small molecule investigational candidate that activates the lanthionine synthetase C-Like 2 (LANCL2) pathway, targeting the gastrointestinal tract. Growing research suggests that the LANCL2 plays an important role in the immunoregulatory process.
Based on preclinical and translational evidence, BT-11, by activating the LANCL2 pathway and modulating the interactions between immunological and metabolic signals in immune cells, creates a favorable regulatory microenvironment in the gut, decreasing the production of key inflammatory mediators and increasing anti-inflammatory molecules within the site of inflammation.
Landos is focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases.


Related Headlines